Business Wire

Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Drug Receives FDA Authorization

CHICAGO--(BUSINESS WIRE)--Emalex Biosciences today announced that the U.S. Food and Drug Administration has authorized the company’s Expanded Access Program (EAP) for ecopipam, an investigational ...
Seeking Alpha

Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (CGTX),, a clinical-stage company developing drugs that treat neurodegenerative disorders, announced that its expanded ...
Business Insider

Merakris Therapeutics Enrolls 30th Subject in Expanded Access Program of MTX-001; Highlights Clinical Progress at SAWC Fall 2025

RESEARCH TRIANGLE PARK, N.C, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics, a regenerative medicine company developing biologically derived therapeutics, announced the enrollment of the 30 ...
Fox 5 San Diego

WideTrial Provides Update on NIH-Funded Expanded Access Program for Investigational ALS Drug MN-166

WideTrial is an integrated service and technology platform that delivers scalable, group-level Expanded Access programs (EAPs) that are easy to participate in and improve patient access to ...
Seeking Alpha

Nuvation Bio Announces Expanded Access Program in the U.S. for Taletrectinib in Advanced ROS1-positive Non-Small Cell Lung Cancer

NEW YORK--(BUSINESS WIRE)-- Nuvation Bio Inc. (NUVB), a global biopharmaceutical company tackling some of the greatest unmet needs in oncology, today announced it has initiated an Expanded Access ...
Morningstar

BrainStorm Announces New Survival Data from Expanded Access Program Cohort: Remarkably 90% of ALS Patients Survived Over 5 Years with NurOwn®

NEW YORK, June 16, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced new survival ...
Nasdaq

Cognition Therapeutics Reaches Full Enrollment in Expanded Access Program for Zervimesine (CT1812) in Dementia with Lewy Bodies

PURCHASE, N.Y., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative ...
MarketWatch

Emalex Biosciences' Expanded Access Program for Investigational Tourette Syndrome Drug Receives FDA Authorization

Emalex Biosciences today announced that the U.S. Food and Drug Administration has authorized the company's Expanded Access Program (EAP) for ecopipam, an investigational therapy in development for the ...